pennystockhaven
  • Facebook
  • Twitter
  • Youtube
  • Rss
Day-Trading Penny Stocks
  • Home
  • Services
  • Contact Us
Home» Street Sense Video » Lpath, Inc. (LPTN): Street Sense Video

Lpath, Inc. (LPTN): Street Sense Video

Posted on July 21, 2012 by PennyStockHaven in Street Sense Video - 3 Comments

Lpath Incorporated (LPTN) Street Sense Video:

Lpath, Inc. (LPTN) is a biotechnology company focused on the discovery and development of monoclonal antibodies targeted to bioactive lipids. Lipid-based therapeutics are an emerging field of medical science whereby bioactive signaling lipids are targeted for treating important human diseases that currently lack innovative and effective medicines.

Pipeline:

iSONEP™ (Phase 2): demonstrated excellent results in various preclinical AMD models and first-in-class results in a preclinical model of diabetic retinopathy. Collaboration agreement with Pfizer Inc. that could result in payments up to $517.5 million plus tiered double digit royalties to Lpath.

ASONEP™ (pre-Phase2): targeted sphingosine-1-phosphate (S1P); might also have applications in other diseases like multiple sclerosis, colitis and other inflammatory disorders.

Lpathomab™ (preclinical): targeted lysophosphatidic acid (LPA) for diseases of the central nervous system, fibrosis, ocular disease and cancer. Demonstrated strong preclinical activity in several animal models of these diseases, including neuropathic pain, diabetic neuropathy, traumatic brain injury, spinal cord injury, fibrosis (pulmonary and renal), and cancer.

Pfizer (NYSE: PFE) provided Lpath with an upfront option payment of $14 million in addition to sharing the cost of the planned iSONEP™ trials. Following completion of the two studies, Pfizer has the right to exercise its option for worldwide rights to iSONEP for an undisclosed option fee and, if Pfizer exercises its option, Lpath will be eligible to receive development, regulatory and commercial milestone payments that could total up to $497.5 million; in addition, Lpath will be entitled to receive tiered double-digit royalties based on sales of iSONEP. As part of the agreement, Lpath has granted to Pfizer a time-limited right of first refusal for ASONEP(TM), Lpath’s product candidate that is being evaluated for the treatment of cancer. Two Phase 2a trials are currently planned to further assess ASONEP’s efficacy and safety in cancer patients.

Analysts estimate:

Morgan Joseph targeted LPTN to $8/share in less than 18 months from now based on the drug candidate worth of $710 million on a risk-adjusted basis with a peak global sales target of $3.6 billion.

Aegis Capital rated Lpath Inc. (LPTN) as a Buy with price target $6/share


iSONEP™ may offer a cure for the wet AMD patients. Fast-track FDA approval is doable.

Renewal of iSONEP™ trials set for early August. Pfizer (NYSE: PFE) acquisition of the Lpath’s ImmuneY2™ drug-discovery engine is feasible.

 

report at this link

 

 

An affiliate of PennyStockHaven.com receives up to fifteen thousand dollars per month for consulting and advisory services related to Lpath. Our relationship with this affiliate constitutes a conflict and may affect the objectivity of our profile of the company. You should do your own homework and consult an investment professional before making any investment decisions. Read our full disclaimer here. 
LPTN

Search

Real Time Alerts:

Tweets by @PennyStockHaven

Updates

  • CVR Partners, LP (NYSE: UAN): the dividend play

    February 26, 2023
  • Sotera Health

    Sotera Health Company (NASDAQ:SHC): hard road ahead

    February 21, 2023
  • ZIM Integrated Shipping Services (NYSE:ZIM) uphill movement

    February 20, 2023
  • Carvana Co. (NYSE: CVNA) way to go… down

    February 17, 2023
  • ReWalk Robotics (RWLK): Yesterday, Today and Tomorrow

    June 8, 2019
  • Amyris, Inc. (AMRS): How to Mislead Investors

    April 21, 2019
  • ADMA Biologics, Inc. (ADMA): Offering is Imminent

    April 11, 2019
  • Proteostasis Therapeutics (PTI): Market Overreaction

    March 26, 2019
  • Dynagas LNG Partners LP (NYSE: DLNG) Coming Off Of Bottom

    February 1, 2019
  • Histogenics Corporation (HSGX) market: only upside from these levels

    September 5, 2018
  • Quantum Corp. (QTM): Appointed Jamie Lerner as Chief Executive Officer and President

    June 26, 2018
  • FuelCell Energy (NASDAQ:FCEL) A picture is worth a thousand words

    June 22, 2018
    Micro & Small Cap Stocks

    * required

    *



    *



     
    Remember, if you’re not fully satisfied with our service, you can always opt-out of receiving our newsletter. We don’t spam and we’ll never sell your email to anyone else. We respect our subscribers’ privacy.

    Site

    • Home
    • Services
    • Contact Us
    • About Us
    • Privacy Policy
    • Terms of Use
    • Disclaimer
    • Publishers

    Financial Network

    Yahoo Finance
    Reuters
    The Motley Fool
    WSJ
    CNBC
    Business Week
    The Street
    Bloomberg

    psh sloganYour Everything Penny Stocks Resource



    Copyright © 2021 PennyStockHaven.com. All Rights Reserved